Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 24, 2009

Xcellerex, Dowpharma, Biopharm, and deltaDot Win $11M Technology Development Contract

  • Xcellerex, Dowpharma, Biopharm Services, and deltaDot have been awarded $11 million to develop technology that accelerates mAb and vaccine manufacturing. DTRA’s Joint Science and Technology Office, Transformational Medical Technologies Initiative granted the phase 2 funding.

    The 12-month phase 1 contract was received from DARPA. The initial stage of the program was aimed at developing a high-efficiency bacterial-expression system using Dowpharma’s Pfenex Expression Technology™ in conjunction with Xcellerex’ single-use FlexFactory platform to grow production strains to high cell densities and to purify the model vaccine and antibody.

    The current effort will work to increase the productivity and speed of process optimization, including demonstration of scale-up and improved economics. This will include optimizing host strains and a manufacturing process required to increase the yield of vaccines and mAbs by 10-fold over that achieved in phase 1 with the added objective of increasing product quality.

    Xcellerex’ microbial PDMax™ high-speed process development technology is also used in the collaboration along with deltaDOT’s Peregrine® label-free, CE-based analytical technology. The team is guided by BioPharm Services’ systems integration, data management/process economics, and simulated event-modeling technology.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »